Zynerba Press Releases

13 Sep 21 Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

9 Sep 21 Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

7 Sep 21 Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

2 Sep 21 Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

2 Sep 21 Zynerba Pharmaceuticals Announces Oral Presentations at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

9 Aug 21 Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

4 Aug 21 Zynerba Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference

7 Jul 21 Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference

30 Jun 21 Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting

11 Jun 21 Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting